1. Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System. Issue 9 (September 2019) Authors: Mohamoud, Mohamed; Patanavanich, Saharat; Crew, Page; McCulley, Lynda; Munoz, Monica; Kortepeter, Cindy; Jones, S. Christopher; Woronow, Daniel; Dal Pan, Gerald Journal: Annals of pharmacotherapy Issue: Volume 53:Issue 9(2019) Page Start: 962 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Issue 5 (May 2022) Authors: Self, Wesley H.; Sandkovsky, Uriel; Reilly, Cavan S.; Vock, David M.; Gottlieb, Robert L.; Mack, Michael; Golden, Kevin; Dishner, Emma; Vekstein, Andrew; Ko, Emily R.; Der, Tatyana; Franzone, John; Almasri, Eyad; Fayed, Mohamed; Filbin, Michael R.; Hibbert, Kathryn A.; Rice, Todd W.; Casey, Jonat... Journal: Lancet infectious diseases Issue: Volume 22:Issue 5(2022) Page Start: 622 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1558. Commensal Neisseria Species as a Cause of Disease in Patients Taking Eculizumab. (26th November 2018) Authors: Crew, Page; McNamara, Lucy; Waldron, Peter; McCulley, Lynda; Jones, S Christopher; Bersoff-Matcha, Susan Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗